CN112566899B - 用于治疗rna病毒感染的苯基-n-喹啉衍生物 - Google Patents

用于治疗rna病毒感染的苯基-n-喹啉衍生物 Download PDF

Info

Publication number
CN112566899B
CN112566899B CN201980045917.4A CN201980045917A CN112566899B CN 112566899 B CN112566899 B CN 112566899B CN 201980045917 A CN201980045917 A CN 201980045917A CN 112566899 B CN112566899 B CN 112566899B
Authority
CN
China
Prior art keywords
group
groups
radicals
alkyl
viral infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980045917.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN112566899A (zh
Inventor
D·谢雷
J·塔泽
F·马于托-贝茨尔
R·纳日曼
J·桑托斯
C·阿波利特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Curie
Wittycell
Universite de Montpellier
Original Assignee
Institut Curie
Wittycell
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Curie, Wittycell, Universite de Montpellier filed Critical Institut Curie
Publication of CN112566899A publication Critical patent/CN112566899A/zh
Application granted granted Critical
Publication of CN112566899B publication Critical patent/CN112566899B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201980045917.4A 2018-07-09 2019-07-09 用于治疗rna病毒感染的苯基-n-喹啉衍生物 Active CN112566899B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18305910.4A EP3594206A1 (en) 2018-07-09 2018-07-09 Phenyl-n-quinoline derivatives for treating a rna virus infection
EP18305910.4 2018-07-09
PCT/EP2019/068459 WO2020011810A1 (en) 2018-07-09 2019-07-09 Phenyl-n-quinoline derivatives for treating a rna virus infection

Publications (2)

Publication Number Publication Date
CN112566899A CN112566899A (zh) 2021-03-26
CN112566899B true CN112566899B (zh) 2024-01-30

Family

ID=63035966

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980045917.4A Active CN112566899B (zh) 2018-07-09 2019-07-09 用于治疗rna病毒感染的苯基-n-喹啉衍生物

Country Status (10)

Country Link
US (3) US12084422B2 (https=)
EP (2) EP3594206A1 (https=)
JP (2) JP7504409B2 (https=)
KR (1) KR102758510B1 (https=)
CN (1) CN112566899B (https=)
AU (1) AU2019300100B2 (https=)
BR (1) BR112021000331A2 (https=)
CU (1) CU24674B1 (https=)
MX (1) MX2021000089A (https=)
WO (1) WO2020011810A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3594206A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection
US20230142547A1 (en) 2020-03-20 2023-05-11 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP3884946A1 (en) 2020-03-25 2021-09-29 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
EP3881844A1 (en) 2020-03-20 2021-09-22 Abivax Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection
IL326865A (en) * 2023-08-30 2026-04-01 Jiangsu Chia Tai Fenghai Pharmaceutical Co Ltd Compound for regulating microRNA activity A-124
WO2025149545A1 (en) * 2024-01-11 2025-07-17 F. Hoffmann-La Roche Ag Heteroarylphenyl ether derivatives

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103415290A (zh) * 2010-12-15 2013-11-27 斯皮利寇斯公司 用于治疗aids的化合物
CN105530938A (zh) * 2013-07-05 2016-04-27 Abivax公司 用于治疗由逆转录病毒引起的疾病的化合物
CN107635559A (zh) * 2015-02-23 2018-01-26 Abivax公司 用于治疗或预防病毒感染的喹啉衍生物
CN107810418A (zh) * 2015-02-23 2018-03-16 Abivax公司 用于筛选用于治疗或预防病毒感染或病毒相关状况的化合物的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
US7429599B2 (en) 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
FR2830862A1 (fr) 2001-10-16 2003-04-18 Lipha Derives nitroso de la diphenylamine a fonction ether ou thioether, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments
FR2836917B1 (fr) 2002-03-11 2006-02-24 Lipha Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif
DE602004020073D1 (de) 2003-08-21 2009-04-30 Osi Pharm Inc 3-substituierte imidazopyridinderivate als c-kit-inhibitoren
FR2859474B1 (fr) 2003-09-04 2006-01-13 Centre Nat Rech Scient Utilisation de composes derives d'indole pour la preparation d'un medicament utile pour le traitement de maladies genetiques resultant de l'alteration des processus d'epissage
EP1697343B1 (en) 2003-12-18 2009-07-01 Tibotec Pharmaceuticals Ltd. Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication
FR2866647B1 (fr) * 2004-02-20 2006-10-27 Servier Lab Nouveaux derives azabicycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2006037117A1 (en) 2004-09-27 2006-04-06 Amgen Inc. Substituted heterocyclic compounds and methods of use
ES2574670T3 (es) 2005-03-17 2016-06-21 Janssen Sciences Ireland Uc 1,3-Dihidro-bencimidazol-2-ilidenoaminas como inhibidores de replicación del virus sincicial respiratorio
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
ATE475660T1 (de) 2005-12-21 2010-08-15 Abbott Lab Antivirale verbindungen
US7915411B2 (en) 2005-12-21 2011-03-29 Abbott Laboratories Anti-viral compounds
FR2901273B1 (fr) 2006-05-19 2010-12-24 Anaconda Pharma Inhibiteurs du virus du papillome humain et les compositions pharmaceutiques les contenant
FR2926297B1 (fr) 2008-01-10 2013-03-08 Centre Nat Rech Scient Molecules chimiques inhibitrices du mecanisme d'epissage pour traiter des maladies resultant d'anomalies d'epissage.
US20140187641A1 (en) 2012-08-23 2014-07-03 Gtx Estrogen receptor ligands and methods of use thereof
SI2440547T1 (sl) 2009-06-12 2023-05-31 Abivax Nove kemične molekule, ki zavirajo mehanizem spajanja za zdravljenje bolezni, ki so posledica napak pri spajanju
JP2011026251A (ja) * 2009-07-27 2011-02-10 Kowa Co 2−アリールアミノキノリン化合物及びこれを有効成分として含有するエリスロポエチン産生促進剤
US8846713B2 (en) 2010-06-24 2014-09-30 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors
EP2505198A1 (en) 2011-04-01 2012-10-03 Société Splicos Compounds for use as therapeutic agents affecting p53 expression and/or activity
WO2014164667A1 (en) 2013-03-11 2014-10-09 Georgetown University Dengue and west nile virus protease inhibitors
RU2628800C2 (ru) 2014-03-12 2017-08-22 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами
US20160143884A1 (en) 2014-11-26 2016-05-26 Esanex, Inc. Use of tetrahydroindazolylbenzamide and tetrahydroindolylbenzamide derivatives for the treatment of human immunodeficiency virus (hiv) and acquired immune deficiency syndrome (aids)
PT3429998T (pt) 2016-03-18 2021-11-04 Prosynergia S A R L Processo para preparação de derivados de quinolin-2-il-fenilamina e seus sais
EP3594206A1 (en) * 2018-07-09 2020-01-15 Abivax Phenyl-n-quinoline derivatives for treating a rna virus infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103415290A (zh) * 2010-12-15 2013-11-27 斯皮利寇斯公司 用于治疗aids的化合物
CN105530938A (zh) * 2013-07-05 2016-04-27 Abivax公司 用于治疗由逆转录病毒引起的疾病的化合物
CN107635559A (zh) * 2015-02-23 2018-01-26 Abivax公司 用于治疗或预防病毒感染的喹啉衍生物
CN107810418A (zh) * 2015-02-23 2018-03-16 Abivax公司 用于筛选用于治疗或预防病毒感染或病毒相关状况的化合物的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis and anti-HCV activity evaluation of anilinoquinoline derivatives;Huang-Kai Peng等;Bioorganic & Medicinal Chemistry Letters;第22卷;1107-1110 *

Also Published As

Publication number Publication date
JP7673362B2 (ja) 2025-05-09
US20260035348A1 (en) 2026-02-05
US12084422B2 (en) 2024-09-10
KR20210052432A (ko) 2021-05-10
CA3103867A1 (en) 2020-01-16
US20240308964A1 (en) 2024-09-19
US20210309611A1 (en) 2021-10-07
MX2021000089A (es) 2021-03-25
US12479802B2 (en) 2025-11-25
EP3820852A1 (en) 2021-05-19
CU24674B1 (es) 2023-08-08
EP3594206A1 (en) 2020-01-15
WO2020011810A1 (en) 2020-01-16
JP7504409B2 (ja) 2024-06-24
AU2019300100A1 (en) 2021-01-21
AU2019300100B2 (en) 2024-10-24
BR112021000331A2 (pt) 2021-04-06
CU20210006A7 (es) 2021-08-06
JP2024053563A (ja) 2024-04-15
JP2021524481A (ja) 2021-09-13
KR102758510B1 (ko) 2025-01-22
CN112566899A (zh) 2021-03-26

Similar Documents

Publication Publication Date Title
CN112566899B (zh) 用于治疗rna病毒感染的苯基-n-喹啉衍生物
CN112703183B (zh) 用于治疗rna病毒感染的芳基-n-芳基衍生物
RU2805064C2 (ru) Производные фенил-n-хинолина для лечения рнк-вирусной инфекции
HK40040036A (en) Phenyl-n-quinoline derivatives for treating a rna virus infection
CA3103867C (en) Phenyl-n-quinoline derivatives for treating an rna virus infection
HK40040036B (zh) 用於治疗rna病毒感染的苯基-n-喹啉衍生物
RU2815493C2 (ru) Арил-n-арильные производные для лечения рнк-вирусной инфекции
RU2803216C2 (ru) Фенил/пиридил-n-фенил/пиридильные производные для лечения рнк-вирусной инфекции
HK40039623A (en) Phenyl/pyridyl-n-phenyl/pyridyl derivatives for treating rna virus infection
HK40040015A (en) Aryl-n-aryl derivatives for treating a rna virus infection
HK40040882A (en) Phenyl/pyridyl-n-phenyl/pyridyl derivatives for treating a rna virus infection
HK40039623B (zh) 用於治疗rna病毒感染的苯基/吡啶基-n-苯基/吡啶基衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40040036

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant